AUS
NZ
UK
CA
USA
IND
Despite a generally buoyant market on Monday, ResMed Inc. (ASX:RMD) found itself under pressure, with its shares declining by 2.14% and closing at AU$30.60. This drop in the stock price followed a significant decline in the company’s NYSE-listed shares on Friday, reflecting broader concerns about the impact of weight loss drugs on demand for sleep disorder treatments.
The primary catalyst for ResMed's share weakness is a sharp sell-off on Wall Street, which was driven by recent developments at DexCom Inc. (NASDAQ:DXCM). DexCom, a manufacturer of glucose monitoring devices, saw its stock plummet by 40%, erasing approximately US$17 billion from its market capitalisation. While DexCom operates in a different sector, focusing on diabetes management, the ripple effects are being felt across related medical device markets.
DexCom's troubles were exacerbated by a troubling update indicating a decline in new customers, reduced revenue per patient, and higher-than-expected rebates. The company revised its revenue guidance downward by up to US$350 million, causing significant investor concern. Mizuho Securities’ Jared Holz expressed surprise at the sudden deterioration, noting the swift and dramatic nature of the decline. Similarly, JP Morgan's Robbie Marcus highlighted a significant erosion of investor confidence following DexCom's update, noting that management’s credibility has been notably shaken.
Although DexCom's issues are specific to its business, there are potential overlaps in the customer bases between DexCom and ResMed. DexCom’s glucose monitors are crucial for type 1 diabetics and also cater to type 2 diabetics, many of whom are affected by weight—a contributing factor to sleep apnea, the primary condition treated by ResMed’s devices. This overlap raises concerns that weight loss drugs, which are often used to manage type 2 diabetes and obesity, might impact demand for ResMed’s sleep apnea treatments.
However, it’s important to consider that the challenges faced by DexCom might not be indicative of a broader trend affecting ResMed. Competitors in the medical device sector, such as Insulet Corp (NASDAQ:PODD) and Abbott Laboratories (NYSE:ABT), continue to show strong performance. Insulet recently reported better-than-expected sales, and Abbott has raised its full-year profit guidance, partly due to robust glucose monitor sales. These developments suggest that DexCom’s issues might be more related to specific competitive dynamics rather than a general decline in market demand driven by weight loss drugs.
Furthermore, ResMed’s long-term growth prospects remain promising. Analysts generally believe that, despite potential reductions in its addressable market due to weight loss drugs, ResMed is well-positioned to continue growing solidly. The company’s upcoming quarterly update on Friday will provide more clarity on its current performance and future outlook.
